IGC Pharma (FRA:IGS1) Total Liabilities: €2.65 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IGS1 IGC Pharma Inc FRA:IGS1
34 GF Score
Price €0.23
GF Value €0.20
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Total Liabilities?

IGC Pharma FRA:IGS1 -1.72% 34 Total Liabilities is €2.65 Mil as of Mar. 2026. GuruFocus rates FRA:IGS1 with a GF Score™ of 34/100 and a GF Value™ of €0.20 (Modestly Overvalued). The stock has 6 warning signs investors should review.

IGC Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was €2.65 Mil.

IGC Pharma's quarterly Total Liabilities increased from Sep. 2025 (€1.41 Mil) to Dec. 2025 (€1.96 Mil) and increased from Dec. 2025 (€1.96 Mil) to Mar. 2026 (€2.65 Mil).

IGC Pharma's annual Total Liabilities increased from Mar. 2023 (€2.12 Mil) to Mar. 2024 (€2.38 Mil) but then declined from Mar. 2024 (€2.38 Mil) to Mar. 2025 (€2.24 Mil).

IGC Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Total Liabilities Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.57 2.67 2.12 2.38 2.24

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 1.62 1.41 1.96 2.65
FRA:IGS1
34GF Score
IGC Pharma Inc FRA:IGS1
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IGC Pharma's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.088+(0.133+0.015
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.24

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=8.091-5.855
=2.24

IGC Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.485+(0.165+2.7755575615629E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.65

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=7.945-5.295
=2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €2.65 Mil mean?
IGC Pharma (FRA:IGS1) has a Total Liabilities of €2.65 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for IGC Pharma and its competitors.
Is IGC Pharma's Total Liabilities too high?
IGC Pharma's current Total Liabilities is €2.65 Mil. Overall, IGC Pharma has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Total Liabilities compare to SER and NRSN?
IGC Pharma's Total Liabilities of €2.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for IGC Pharma and its competitors. IGC Pharma's current Total Liabilities is €2.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (FRA:IGS1) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.20, compared to a current price of €0.23 — trading 14% above its estimated fair value. The current Total Liabilities is €2.65 Mil. IGC Pharma's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For IGC Pharma (FRA:IGS1), the current Total Liabilities is €2.65 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (FRA:IGS1) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of €0.23 is trading 14% above its estimated GF Value™ of €0.20. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for FRA:IGS1:

  • Total Liabilities: €2.65 Mil
  • GF Value™: €0.20 vs. price of €0.23 (14% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the FRA:IGS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGC:USA
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
34GF Score

Get the complete analysis for FRA:IGS1

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.20
GF Value